Monopar Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax
Monopar Therapeutics Inc. (MNPR) reported Other Comprehensive Income (Loss), Net of Tax of $12.10 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-03-23
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was $21.21K.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-03-31 was -$584.00, a 121.05% decline year-over-year.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2021-09-30 was $9.00, a 99.40% decline year-over-year.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2021-06-30 was -$57.00, a 101.65% decline year-over-year.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for fiscal 2022 was $12.10K, a 156.78% increase from fiscal 2021.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for fiscal 2021 was $4.71K, a 52.18% increase from fiscal 2020.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for fiscal 2020 was $3.10K.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax for fiscal 2019 was -$8.57K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $12.10K 10-K · filed 2023-03-23 | |||
| 2022-06-30 | $21.21K 10-Q · filed 2022-08-11 | $20.63K derived: sum of 2 quarters · filed 2022-08-11 | ||
| 2022-03-31 | -$584.00 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $4.71K 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $9.00 10-Q · filed 2022-11-10 | -$48.00 derived: sum of 2 quarters · filed 2022-11-10 | $2.73K derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$57.00 10-Q · filed 2022-08-11 | $2.72K derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $2.77K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $3.10K 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $1.51K 10-Q · filed 2021-11-12 | $4.97K derived: sum of 2 quarters · filed 2021-11-12 | $926.00 derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $3.46K 10-Q · filed 2021-11-12 | -$584.00 derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | -$4.04K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | -$8.57K 10-K · filed 2021-03-25 | |||
| 2019-09-30 | -$8.74K 10-Q · filed 2020-11-12 | -$7.67K derived: sum of 2 quarters · filed 2020-11-12 | -$9.80K derived: sum of 3 quarters · filed 2020-11-12 | -$9.81K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $1.07K 10-Q · filed 2020-11-12 | -$1.06K derived: sum of 2 quarters · filed 2020-11-12 | -$1.07K derived: sum of 3 quarters · filed 2020-11-12 | -$1.88K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-03-31 | -$2.13K 10-Q · filed 2020-11-12 | -$2.14K derived: sum of 2 quarters · filed 2020-11-12 | -$2.94K derived: sum of 3 quarters · filed 2020-11-12 | -$4.52K derived: sum of 4 quarters · filed 2020-11-12 |
| 2018-12-31 | -$11.00 10-Q · filed 2019-11-12 | -$817.00 derived: sum of 2 quarters · filed 2019-11-12 | -$2.40K derived: sum of 3 quarters · filed 2019-11-12 | -$2.40K 10-K · filed 2020-03-27 |
| 2018-09-30 | -$806.00 10-Q · filed 2019-11-12 | -$2.38K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-06-30 | -$1.58K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |